The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel. Zevaskyn is an autologous cell-based gene therapy for the treatment of wounds in adult and paediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). “Today’s approval of Zevaskyn represents a pivotal moment in the treatment […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!